Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) Thursday reported a loss for the second quarter compared to a profit last year, as costs increased, despite increased revenues.
The company reported a net loss of $21.6 million or $0.07 per share for the quarter compared to a profit of $56.36 million or $0.17 per share last year.
On a cash earnings per share basis, adjusted income was $1.01 per share compared to $0.73 last year.
Total revenues increased to $820.09 million from $609.39 million.
Legal settlements surged to $53.62 million from $2 million and amortization of intangible assets climbed to $210.57 million from $114.95 million. Further, the company raised its cash earnings per share outlook to $4.55 to $4.75, or $4.18 to $4.38 excluding one-time items, from the prior guidance of $4.45 to $4.70.
The company maintains its revenue forecast of $3.4 to $3.6 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.